



HAL
open science

CF₂H as hydrogen bond donor group for the fine tuning of peptide bond geometry with difluoromethylated pseudoprolines

N Malquin, K Rahgoshay, N Lensen, G Chaume, E Miclet, Thierry Brigaud

► **To cite this version:**

N Malquin, K Rahgoshay, N Lensen, G Chaume, E Miclet, et al.. CF₂H as hydrogen bond donor group for the fine tuning of peptide bond geometry with difluoromethylated pseudoprolines. *Chemical Communications*, 2019, 55 (83), pp.12487-12490. 10.1039/C9CC05771D . hal-03549249

HAL Id: hal-03549249

<https://hal.science/hal-03549249v1>

Submitted on 31 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ChemComm

Chemical Communications

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: N. Malquin, K. Rahgoshay, N. Lensen, G. Chaume, E. Miclet and T. Brigaud, *Chem. Commun.*, 2019, DOI: 10.1039/C9CC05771D.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

COMMUNICATION


CF₂H as hydrogen bond donor group for the fine tuning of peptide bond geometry with difluoromethylated pseudoprolinesN. Malquin,^a K. Rahgoshay,^a N. Lensen,^{*a} G. Chaume,^{*a} E. Miclet^b and T. Brigaud^{*a}Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

CF₂H-pseudoprolines obtained from difluoroacetaldehyde hemiacetal and serine are stable proline surrogates. The consequence of the incorporation of the CF₂H group is an important decrease of the *trans* to *cis* amide bond isomerisation energy and a remarkable stabilisation of the *cis* conformer by an hydrogen bond.

Because of the unique properties of fluorine atom, fluorinated compounds are increasingly recognized as highly promising for the discovery of new bioactive compounds.¹ Considering the specific case of peptides, the incorporation of fluorinated amino acids in peptides has been shown to impart remarkable properties.² It can modulate the peptide conformation and assembly,³ the local hydrophobicity,^{2,4} and the resistance towards proteolysis.⁵ Moreover fluorine atoms are very useful as highly sensitive labels for ¹⁹F-NMR spectroscopy because of ¹⁹F 100% natural abundance and the absence of background signals in natural and biological media.⁶ Although several methods have been reported for the synthesis of trifluoromethylated amino acids, the preparation of difluoromethylated one's is much less common.^{2,7} It is a lack because the CF₂H group presents unique features and we believe that this group will play an increasing role in peptides chemistry. The main property of the CF₂H group is to act as a lipophilic hydrogen bond donor group bioisostere of a hydroxyl or a thiol.⁸ These original bioisosteric properties have recently been highlighted in medicinal chemistry.⁹ Because of its cyclic structure, the proline residue is recognized to play a unique and crucial role on peptide backbone conformation. When included into a peptide, the pyrrolidine ring cannot act as an hydrogen bond donor and restrain the ϕ dihedral angle to about -60° .¹⁰ The Xaa-Pro peptide bond is characterized by a small free energy difference (ΔG^\ddagger_{tc}) between the *trans* and the

cis amide bond conformers, combined with a high activation energy (ΔG^\ddagger_{tc}) for the *cis-trans* isomerization.¹¹ This isomerisation is considered to play a key role in regulating many important biological processes in proline containing peptides and proteins, including protein folding.¹² However, studies of protein folding or control of the peptide or protein function are often hampered by the heterogeneity of the X-Pro peptide bond geometry and the scientific community has constantly been on the lookout for either a *cis* or a *trans* stabilizing proline analogue or surrogate.¹³ In the fluorinated series, CF₃-substituted prolines have recently emerged as very attracting tools for the control of peptides conformation and hydrophobicity.¹⁴ On the other hand, very few examples of difluoromethylated prolines have been reported in the literature,¹⁵ and to our knowledge the synthesis of enantiopure 5-CF₂H-prolines has not been reported so far. Pseudoprolines (Ψ Pro) obtained from the condensation of serine and aldehydes appear as very useful surrogates of δ -substituted prolines to control the conformation of peptides.¹⁶ Since several years we investigate the scope of trifluoromethylated pseudoprolines (CF₃- Ψ Pro) in peptide chemistry.¹⁷ We reported that the ratio of *cis* conformation of the Xaa-CF₃- Ψ Pro peptide bond is increased compared to proline itself. The 2-(*S*)-CF₃- Ψ Pro presents a γ -*endo* puckering of the oxazolidine ring while the 2-(*R*)-CF₃- Ψ Pro adopts a γ -*exo* puckering (Fig. 1).¹⁷ Moreover, a remarkable feature of the 2-(*R*)-CF₃- Ψ Pro is the decrease of the *trans* to *cis* isomerization barrier of the amide bond (-4.17 kcal.mol⁻¹ compared to proline).¹

Fig. 1 Peptidyl bond isomerization and puckering of CF₃- Ψ Pro


^a Laboratory of Chemical Biology (LCB, EA 4505), Université de Cergy-Pontoise, 5 Mail Gay-Lussac, 95000 Cergy-Pontoise, France.

^b Sorbonne Université, École normale supérieure, PSL University, CNRS, Laboratoire des Biomolécules, 75005 Paris, France.

† Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

COMMUNICATION




Scheme 1 Synthesis of H-Ser($\Psi^{CF_2H,H}$ Pro)-OBn (*S,S*)-1 and (*R,S*)-1

Considering the growing importance of the difluoromethyl group, we wish to present herein our results dedicated to difluoromethylated pseudoproline (CF_2H - Ψ Pro). A particular attention is paid to the possibility of interactions through hydrogen bonds.

The oxazolidine ring of the CF_2H -pseudoproline was built by condensation of difluoroacetaldehyde ethyl hemiacetal with serine benzyl ester under an acidic catalysis (Scheme 1). Both diastereomers (*S,S*)-1 and (*R,S*)-1 were conveniently separated by silica gel chromatography. According to our previous investigations in the trifluoromethylated series,^{17a} the *cis* relative configuration of (*R,S*)-1 has been assigned by nuclear Overhauser effect experiments showing a correlation between the C_α and the C_δ protons. In order to investigate the electronic and geometric consequences due to the CF_2H group incorporation of CF_2H - Ψ Pro in a peptide chain, the Ac- Ψ Pro-NHMe model tripeptides (*S,S*)-4 and (*R,S*)-4 have been synthesized in a multi-step procedure (Scheme 2). The *N*-acetylation of (*S,S*)-1 with acetic anhydride under iodine catalysis provided a mixture of Ac- Ψ Pro-OBn (*S,S*)-2 (21%) and (*R,S*)-2 (39%). In order to circumvent the epimerization of the C_δ atom through an acidic catalysis,^{17a,b} the reaction was performed with acetyl chloride in pyridine. These experimental conditions led to the expected *N*-acetylated oxazolidines (*S,S*)-2 and (*R,S*)-2 in 81% and 75% yield respectively without epimerisation.

The *cis/trans* ratio of the acetyl- Ψ Pro bond was determined by 1H and ^{19}F NMR integration in $CDCl_3$. For that purpose, we first assigned each conformers by comparing the α , β , and γ ^{13}C chemical shifts of the *cis* and the *trans* isomers according to Lubell et al.^{18a} For the *trans* isomer, the α and β -carbons appear upfield while they appear downfield in the *cis* isomer. Conversely, the δ carbon for the *trans* isomer appears downfield relative to that of the *cis* isomer. Once acetylated on their *N*-terminal position, we checked the acidic stability of the CF_2H -oxazolidines (*S,S*)-2 and (*R,S*)-2. Experiments showed that, similarly to the CF_3 - Ψ Pro, they are stable in an acidic medium (5% TFA in $CHCl_3$), whereas pseudoproline of the non-fluorinated series are generally prone to ring opening.^{16a} Even when exposed to more concentrated acidic medium for several hours (3h in TFA/ H_2O 95:5) no ring opening or epimerization occurred. The CF_2H -oxazolidines are therefore suitable for SPPS strategy.



^a *cis/trans* conformers ratio of the peptidyl- Ψ Pro bond measured by NMR in $CDCl_3$

Scheme 2 Synthesis of Ac- Ψ Pro-NHMe (*S,S*)-4 and (*R,S*)-4

After removal of the benzyl ester function by hydrogenolysis in quantitative yields, the *N*-methyl amides (*S,S*)-4 and (*R,S*)-4 were obtained in 40% and 33% yield using classical peptide coupling conditions (Scheme 2).

The *cis-trans* bond isomerisation of the CF_2H -oxazolidine-containing peptide models (*S,S*)-4 and (*R,S*)-4 was studied by 1H NMR analysis in water at various temperatures. The coalescence temperatures were determined to estimate the rotational barriers for the *cis-trans* isomerisation. The results are reported in the Table 1 and compared with those reported for regular proline¹⁸ and pseudoproline^{17c} as well as those previously obtained in the CF_3 series.^{17c} The difference of isomerisation energy between the two diastereomers of the CF_3 series (ca. 2.5 kcal.mol⁻¹) is no longer observed in the CF_2H series, the energy barriers are low for both CF_2H -pseudoproline. It is interesting to note that the energy barriers for amide isomerisation of both CF_2H -pseudoproline is ca 5.0 kcal.mol⁻¹ lower than for proline.¹⁸

The *cis* amide bond contents were significantly higher when the CF_3 substituent was replaced by the CF_2H group. Indeed in the apolar chloroform solution, the *cis* population of (*S,S*)-4 reached even 78%. This enrichment may be due to the presence of a new H-bond involving the CF_2H group.⁸ Conversely, it was previously demonstrated that the *trans* amide bond conformer of the 2-(*R*)- CF_3 - Ψ Pro analogue was stabilized by a H-bond between the *C*-terminal amide NH and the carbonyl of the *N*-terminal acetyl group.^{17c} Two antagonist H-bonds may thus compete in the compound (*R,S*)-4 (Fig. 2). This balance was slightly in favour of the CF_2H H-bond in water (53% *cis* population) and underlines the hydrophobicity of the fluorinated group which partially preserves the stability of the H-bond in polar solvents such as methanol and water (see supplementary information).

Finally, the puckerings of the CF_2H -five-membered rings were determined by NMR from the coupling constants between the α and the β protons as previously reported in the CF_3 series (see supplementary information).^{17c}

The results showed that the Ac-(2*S*,4*S*)- CF_2H - Ψ Pro-NHMe (*S,S*)-4 adopted a γ -*endo* pucker conformation for the two

Table 1 Thermodynamic properties of (*S,S*)-4 and (*R,S*)-4 determined by NMR. ^(a) Populations (%) observed in $CDCl_3$. ^(b) Populations (%) and ^(c) energies observed in $H_2O:D_2O$ 90:10. All energies are given in kcal.mol⁻¹

	Pro	Ψ Pro (ref 17c)	2-(<i>S</i>)- CF_3 - Ψ Pro (ref 17c)	2-(<i>S</i>)- CF_2H - Ψ pro (<i>S,S</i>)-4	2-(<i>R</i>)- CF_2H - Ψ pro (<i>R,S</i>)-4	2-(<i>R</i>)- CF_3 - Ψ Pro (ref 17c)
<i>cis/trans</i> ^(a)	13:87 (ref 18b)	27:73	40:60	78:22	32:68	24:76
<i>cis/trans</i> ^(b)	24:76 (ref 18b)	34:66	43:57	60:40	53:47	45:55
ΔG_{t-c}^\ddagger ^(c)	20.40 (ref 18a)	18.41	18.06	15.19	15.82	15.63
ΔG_{c-t}^\ddagger ^(c)	19.83 (ref 18a)	17.93	17.88	15.45	15.90	15.51





Fig. 2 Possible intramolecular H-bonds for Ac- Ψ Pro-NHMe (*S,S*)-**4** and (*R,S*)-**4**

geometries of the peptide bond. The same observation was made for the 2-(*S*)-CF₃- Ψ Pro analogue.^{17c} Conversely the compound (*R,S*)-**4** underwent a puckering switch when the amide bond geometry was reversed.

Instead of maintaining an *exo*-puckered oxazolidine ring for both the *cis* and the *trans* amide conformers, as observed with 2-(*R*)-CF₃- Ψ Pro,^{17c} the *cis* rotamer of (*R,S*)-**4** showed a slight preference for the *endo* puckering to allow the CF₂H H-bond. These structural features can be understood by analyzing the unusual NMR parameters of the CF₂H groups. First, a high chemical shift difference ($\Delta\delta$) of the diastereotopic ¹⁹F informed about a restricted dynamic of the difluoromethyl group. For the *cis* conformers, $\Delta\delta$ was above 5 ppm, whereas $\Delta\delta \approx 3$ ppm for their corresponding *trans* conformations (see Fig. 3 and supplementary information). Second, the measured vicinal couplings reflected a very limited rotameric averaging of the CF₂H group for the *cis* conformers. In particular the Ac-(2*S*,4*S*)-CF₂H- Ψ Pro-NHMe (*S,S*)-**4** displayed the following values: ³J_{H δ -F₁ = 3.2 Hz; ³J_{H δ -F₂ = 18.2 Hz; ³J_{H δ -H δ = 1.0 Hz. These three couplings are compatible with a single H^c-C^c-C ^{δ} -H ^{δ} dihedral angle of $\sim 50^\circ$ (see supplementary information). Such a restricted rotation of the CF₂H group likely arose from the H-bonding observed in the *cis* forms since the oxygen of the preceding acetyl group is facing the positively charged CF₂H proton in this conformation (Fig. 3). The *endo* puckering of the oxazolidine ring may be needed for the CF₂H H-bonding establishment in the *cis* conformers, whereas the *exo* puckering was required for the NH...O=C H-bond in the *trans* form.^{17c} This provides an explanation for the *trans*-*exo* to *cis*-*endo* transition observed for the compound (*R,S*)-**4**. The (*S,S*)-**4** diastereoisomer adopts preferentially the *endo* conformation which explains the high stability of the CF₂H...O=C H-bond in the *cis* conformer. In the *trans* conformers, the CF₂H group cannot establish any H-bond since the O=C acceptor of the acetyl is moved away and replaced by the methyl group. As a result, several rotamers of the CF₂H group are present as attested by the averaged NMR parameters (Fig. 3).}}}

In order to expand the scope of the incorporation of CF₂H-pseudoproline in peptides, a preliminary methodological study of the peptide coupling reactions at their *N*- and *C*-position was undertaken. We already demonstrated that the presence of a CF₃ group at the δ position of an oxazolidine unit is detrimental for coupling reactions because of its powerful withdrawing effect. Although the CF₂H group is less deactivating, typical protocols using HOBt, EDCI, DIPEA or IBCF reagents failed to achieve the *N*-coupling reaction of (*S,S*)-**1** and (*R,S*)-**1** with Fmoc-Gly-OH. However, the peptide coupling could be achieved in good yields while using the most electrophilic Fmoc protected glycine and alanine amino acid chloride (Scheme 3). When the reaction was performed in the presence of pyridine, the epimerization of the δ carbon of the oxazolidine ring through a dynamic kinetic resolution (DKR) process^{17b} was avoided or limited. The expected dipeptides (*S,S*)-**5**, (*R,S*)-**5**, (*S,S*)-**6** and (*R,S*)-**6** were obtained in 86%, 76%, 57% and 88% yield respectively (Scheme 3). It should be



^a *cis/trans* conformers ratio of the peptidyl- Ψ Pro bond measured by NMR in CDCl₃

Scheme 3 Incorporation of CF₂H-pseudoproline in a peptide chain

noticed that in any cases the *cis* conformer of the amide bond was the major one. The *cis/trans* conformers ratio of the peptidyl- Ψ Pro bond measured by NMR in CDCl₃ were ranging from 58/42 to 83/17. After having successfully solved the challenging coupling reaction at the *N*-terminal positions of the CF₂H-pseudoproline, suitable experimental conditions were investigated for the *C*-terminal coupling. The removal of the benzyl ester was carried out by palladium mediated hydrogenolysis without impacting the *N*-Fmoc protecting group. The free carboxylic acid was then used in the next step without further purification. Typical protocols involving HOBt, EDCI, DIPEA at room temperature were not suitable for the coupling reaction between dipeptides **6** and HCl.H₂N-Ala-O^tBu. However, the coupling of the CF₂H-dipeptides using BOP-Cl in the presence of TEA afforded the expected tripeptides (*S,S*)-**7** and (*R,S*)-**7** in 56% and 63% yield respectively. ¹⁹F and ¹H NMR measurements in CDCl₃ revealed a 85/15 *cis/trans* ratio for (*S,S*)-**7** and 59/41 for (*R,S*)-**7**.

In conclusion, original enantiopure (*S,S*) and (*R,S*) CF₂H-pseudoproline have been synthesized as stable 5-substituted proline surrogates which can be incorporated in a peptide chain. The CF₂H group provides a strong decrease of the *trans* to *cis* amide bond isomerisation energy and enhances the *cis* conformation content compared to the CF₃ series, by acting as an efficient hydrogen bond donor. These CF₂H-proline surrogates will provide outstanding tools for the fine tuning of the dynamic and the secondary structure of peptides, in particular type VI β -turns.^{13d} Such conformations are known to play important roles in protein structures and molecular recognition. New non-natural amino acids able to stabilize the *cis*-isomer backbone geometry and/or type VI β -turns are still in demand for the design of potent and selective prototypes for drug discovery.¹⁹

The authors gratefully acknowledge Central Glass Co. for the gift of difluoroacetaldehyde hemiacetal and the Agence Nationale de la Recherche for funding (ANR CH2PROBE and ANR F-LAIR). K. R. thanks the MNREST for a fellowship.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- (a) S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, *Chem. Soc. Rev.*, 2008, **37**, 320; (b) N. A. Meanwell *J. Med. Chem.*, 2018, **61**, 5822; (c) E. P. Gillis, K. J. Eastman, M. D. Hill, D. J. Donnelly and N. A. Meanwell, *J. Med. Chem.*, 2015, **58**, 8315; (d) W. K. J. Hagmann, *J. Med. Chem.*, 2008, **51**,




Fig. 3 NMR parameters and conformational features of (*S,S*)-**4**

- 4359; (e) J. Wang, M. Sánchez-Roselló, J. L. Aceña, C. del Pozo, A. E. Sorochinsky, S. Fustero, V. A. Soloshonok and H. Liu, *Chem. Rev.*, 2014, **114**, 2432; (f) Y. Zhou, J. Wang, Z. Gu, S. Wang, W. Zhu, J. L. Aceña, V. A. Soloshonok, K. Izawa and H. Liu, *Chem. Rev.*, 2016, **116**, 422.
- 2 (a) A. A. Berger, J.-S. Völler, N. Budisa and B. Kocsch, *Acc. Chem. Res.*, 2017, **50**, 2093; (b) E. N. G. Marsh, *Acc. Chem. Res.*, 2014, **47**, 2878; (c) M. Salwiczek, E. K. Nyakatura, U. I. M. Gerling, S. Ye and B. Kocsch, *Chem. Soc. Rev.*, 2012, **41**, 2135.
- 3 U. I. M. Gerling, M. Salwiczek, C. D. Cadicamo, H. Erdbrink, C. Czekelius, S. L. Grage, P. Wadhvani, A. S. Ulrich, M. Behrends, G. Haufe and B. Kocsch, *Chem. Sci.*, 2014, **5**, 819.
- 4 (a) C. Gadais, E. Devillers, V. Gasparik, E. Chelain, J. Pytkowicz and T. Brigaud, *ChemBioChem*, 2018, **19**, 1026; (b) J. R. Robalo, S. Huhmann, B. Kocsch and A. Vila Verde, *Chem*, 2017, **3**, 881.
- 5 (a) S. Huhmann and B. Kocsch, *Eur. J. Org. Chem.*, 2018, 3667; (b) V. Asante, J. Mortier, G. Wolber and B. Kocsch, *Amino Acids*, 2014, **46**, 2733; (c) G. Akcay and K. Kumar, *J. Fluorine Chem.*, 2009, **130**, 1178.
- 6 For review on the use of ¹⁹F NMR, see: (a) E. N. G. Marsh and Y. Suzuki, *ACS Chem. Biol.*, 2014, **9**, 1242; (b) A. Vulpetti and C. Dalvit, *Drug Discov. Today*, 2012, **17**, 890; (c) K. Koch, S. Afonin, M. Ieronimo, M. Berditsch and A. S. Ulrich, *Top. Curr. Chem.*, 2012, **306**, 89; (d) K. E. Arntson and W. C. K. Pomerantz, *J. Med. Chem.*, 2016, **59**, 5158.
- 7 Y.-G. Lou, A.-J. Wang, L. Zhao, L.-F. He, X.-F. Li, C.-Y. He and X. Zhang, *Chem. Commun.*, 2019, **55**, 3705.
- 8 (a) Y. Zafrani, D. Yeffet, G. Sod-Moriah, A. Berliner, D. Amir, D. Marciano, E. Gershonov and S. Saphier, *J. Med. Chem.*, 2017, **60**, 797; (b) C. D. Sessler, M. Rahm, S. Becker, J. M. Goldberg, F. Wang and S. J. Lippard, *J. Am. Chem. Soc.*, 2017, **139**, 9325; (c) J. A. Erickson and J. I. McLoughlin, *J. Org. Chem.*, 1995, **60**, 1626; (d) Q. A. Huchet, B. Kuhn, B. Wagner, N. A. Kratochwil, H. Fischer, M. Kansy, D. Zimmerli, E. M. Carreira and K. Müller, *J. Med. Chem.*, 2015, **58**, 9041; (e) A. Meanwell, *J. Med. Chem.*, 2011, **54**, 2529.
- 9 (a) B. Zheng, S. V. D'Andrea, L.-Q. Sun, A. X. Wang, Y. Chen, P. Hrcnciar, J. Friborg, P. Falk, D. Hernandez, F. Yu, A. K. Sheaffer, J. O. Knipe, K. Mosure, R. Rajamani, A. C. Good, K. Kish, J. Tredup, H. E. Klei, M. Paruchuri, A. Ng, Q. Gao, R. A. Rampulla, A. Mathur, N. A. Meanwell, F. McPhee and P. M. Scola, *ACS Med. Chem. Lett.*, 2018, **9**, 143; (b) T. Naret, J. Bignon, G. Bernadat, M. Benckekroun, H. Levaique, C. Lenoir, J. Dubois, A. Pruvost, F. Saller, D. Borgel, B. Manoury, V. Leblais, R. Darrigrand, S. Apcher, J. D. Brion, E. Schmitt, F. R. Leroux, M. Alami and A. Hamze, *Eur. J. Med. Chem.*, 2018, **143**, 473; (c) F. Narjes, K. F. Koehler, U. Koch, B. Gerlach, S. Colarusso, C. Steinkühler, M. Brunetti, S. Altamura, R. De Francesco and V. G. Matassa, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 701; (d) S. Thompson, S. A. McMahon, J. H. Naismith and D. O'Hagan, *Bioorg. Chem.*, 2016, **64**, 37.
- 10 F. A. Momany, R. F. McGuire, A. W. Burgess and H. A. Scheraga, *J. Phys. Chem.*, 1975, **79**, 2361.
- 11 (a) S. S. Zimmerman and H. A. Scheraga, *Macromolecules*, 1976, **9**, 408; (b) D. E. Stewart, A. Sarkar and J. E. Wampler, *J. Mol. Biol.*, 1990, **214**, 253; (c) S. Fischer, R. L. Dunbrack and M. Karplus, *J. Am. Chem. Soc.*, 1994, **116**, 11931; (d) D. Kern, M. Schutkowski and T. Drakenberg, *J. Am. Chem. Soc.*, 1997, **119**, 8403.
- 12 (a) M. Levitt, *J. Mol. Biol.*, 1981, **145**, 251; (b) A. J. Salahuddin, *J. Biosci.*, 1984, **6**, 349; (c) W. J. Wedemeyer, E. Welker and H. A. Scheraga, *Biochemistry*, 2002, **41**, 14637; (d) *Mechanisms of Protein Folding*, Ed. R. H. Pain, Oxford University Press, New York, 1994; (e) J. F. Brandts, H. R. Halvorson and M. Brennan, *Biochemistry*, 1975, **14**, 4953; (f) U. Reimer, G. Scherer, M. Drewello, S. Kruber, M. Schutkowski and G. Fischer, *J. Mol. Biol.* 1998, **279**, 449; (g) P. A. M. Schmidpeter, J. R. Koch and F. X. Schmid, *Biochim. Biophys. Acta*, 2015, **1850**, 1973; (h) W. J. Wedemeyer, E. Welker and H. A. Scheraga, *Biochemistry*, 2002, **41**, 14637.
- 13 (a) P. Karoyan, S. Sagan, O. Lequin, J. Quancard, S. Lavielle and G. Chassaing, in *Targets in Heterocyclic Systems-Chemistry and Properties*, O. A. Eds Attanasi, D. Spinelli, Royal Society of Chemistry, Cambridge, 2005, pp 216–273; (b) *Cis-Trans Isomerization in Biochemistry*, Ed. C. Dugave, Wiley-VCH, Weinheim, 2006; (c) C. Dugave and L. Demange, *Chem. Rev.*, 2003, **103**, 2475; (d) Y. Che and G. R. Marshall, *Biopolymers*, 2006, **81**, 392.
- 14 (a) V. Kubyskhin, S. Pridma and N. Budisa, *New J. Chem.*, 2018, **42**, 13461 and refs cited; (b) N. A. Tolmachova, I. S. Kondratov, V. G. Dolovanyuk, S. O. Pridma, A. V. Chernykh, C. G. Daniliuc and G. Haufe, *Chem. Commun.*, 2018, **54**, 9683; (c) S. J. M. Verhoorck, P. M. Killoran and C. R. Coxon, *Biochemistry*, 2018, **57**, 6132; (d) M. Oliver, C. Gadais, J. García-Pindado, M. Teixidó, N. Lensen, G. Chaume and T. Brigaud, *RSC Adv.*, 2018, **8**, 14597; (e) C. Caupène, G. Chaume, L. Ricard and T. Brigaud, *Org. Lett.*, 2009, **11**, 209; (f) I. Jllia, N. Lensen, G. Chaume, E. Dzhambazova, L. Astasidi, R. Hadjiolova, A. Bocheva and T. Brigaud, *Eur. J. Med. Chem.*, 2013, **62**, 122; (g) J. Simon, J. Pytkowicz, N. Lensen, G. Chaume and T. Brigaud, *J. Org. Chem.*, 2016, **81**, 5381; (h) H. Lubin, J. Pytkowicz, G. Chaume, G. Sizun-Thomé and T. Brigaud, *J. Org. Chem.*, 2015, **80**, 2700; (i) V. Kubyskhin, S. Afonin, S. Kara, N. Budisa, P. K. Mykhailiuk and A. S. Ulrich, *Org. Biomol. Chem.*, 2015, **13**, 3171; (j) I. S. Kondratov, V. G. Dolovanyuk, N. Tolmachova, I. I. Gerus, K. Bergander, R. Fröhlich and G. Haufe, *Org. Biomol. Chem.*, 2012, **10**, 8778; (k) N. G. Voznesenskaia, O. I. Shmatova, V. N. Khrustalev and V. G. Nenajdenko, *Org. Biomol. Chem.*, 2018, **16**, 7004; (l) J. Del Valle and M. Goodman, *Angew. Chem., Int. Ed.*, 2002, **41**, 1600; (m) X.-l. Qiu and F.-l. Qing, *J. Org. Chem.*, 2002, **67**, 7162.
- 15 (a) R. Nadano, Y. Iwai, T. Mori and J. Ichikawa, *J. Org. Chem.*, 2006, **71**, 8748; (b) X. L. Qiu and F. L. Qing, *J. Org. Chem.*, 2003, **68**, 3614; (c) R. C. McAtee, J. W. Beatty, C. C. McAtee and C. R. J. Stephenson, *Org. Lett.*, 2018, **20**, 3491.
- 16 (a) T. Wöhr and M. Mutter, *Tetrahedron Lett.*, 1995, **36**, 3847; (b) P. Dumy, M. Keller, D. E. Ryan, B. Rohwedder, T. Wöhr and M. Mutter, *J. Am. Chem. Soc.*, 1997, **119**, 91; (c) M. Keller, C. Sager, P. Dumy, M. Schutkowski, G. S. Fischer and M. Mutter, *J. Am. Chem. Soc.*, 1998, **120**, 2714.
- 17 (a) G. Chaume, O. Barbeau, P. Lesot and T. Brigaud, *J. Org. Chem.*, 2010, **75**, 4135; (b) G. Chaume, J. Simon, C. Caupene, N. Lensen, E. Miclet and T. Brigaud, *J. Org. Chem.*, 2013, **78**, 10144; (c) D. Feytens, G. Chaume, G. Chassaing, S. Lavielle, T. Brigaud, B. J. Byun, Y. K. Kang, E. Miclet, *J. Phys. Chem. B*, 2012, **116**, 4069; (d) G. Chaume, D. Feytens, G. Chassaing, S. Lavielle, T. Brigaud and E. Miclet, *New J. Chem.*, 2013, **37**, 1336; (e) G. Chaume, J. Simon, N. Lensen, J. Pytkowicz, T. Brigaud and E. Miclet, *J. Org. Chem.*, 2017, **82**, 13602.
- 18 (a) E. Beausoleil and W. D. Lubell, *J. Am. Chem. Soc.*, 1996, **118**, 12902; (b) C. B. Braga, W. G. D. P. Silva and R. Rittner, *New J. Chem.* 2019, **43**, 1757.
- 19 For a recent example see R. Chingle, M. Mulumba, N. N. Chung, T. M.-D. Nguyen, H. Ong, S. Ballet, P. W. Schiller and W. D. Lubell, *J. Org. Chem.*, 2019, **84**, 6006 and cited references.